<DOC>
	<DOCNO>NCT00045279</DOCNO>
	<brief_summary>RATIONALE : PEG-interferon alfa-2b may stop growth kidney cancer stop blood flow tumor . PURPOSE : Phase II trial study effectiveness PEG-interferon alfa-2b treat patient metastatic kidney cancer .</brief_summary>
	<brief_title>PEG-Interferon Alfa-2b Treating Patients With Metastatic Kidney Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy PEG-interferon alfa-2b patient metastatic renal cell carcinoma . - Determine time disease progression patient treat drug . - Determine safety drug patient . - Determine quality life patient treated drug . - Determine effect drug biological surrogate antitumor activity ( basic fibroblast growth factor , vascular endothelial growth factor , interleukin-6 serum level ) patient . OUTLINE : Patients receive PEG-interferon alfa-2b subcutaneously weekly . Courses repeat every 4 week absence disease progression unacceptable toxicity . Quality life assess baseline , 2 week 2 , 4 , 8 , 12 month initiation study therapy , completion study therapy . PROJECTED ACCRUAL : A total 45 patient accrue study within 15 month .</detailed_description>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm renal cell carcinoma Metastatic disease No prior therapy advanced disease Tumor sample available molecular analysis prior registration MSKCC IRB # 89076 Bidimensionally measurable disease No brain metastasis unless completely resect without evidence recurrence least six month PATIENT CHARACTERISTICS : Age 18 Performance status Karnofsky 70100 % Life expectancy Not specify Hematopoietic WBC least 3,000/mm3 Platelet count least 100,000/mm3 Hepatic Bilirubin great 1.5 mg/dL SGOT great 2.5 time upper limit normal ( unless due hepatic metastasis ) Hepatitis B surface antigen negative Hepatitis C negative Renal Creatinine great 2 mg/dL Cardiovascular No severe cardiac disease No New York Heart Association class III IV cardiac disease No myocardial infarction within past 12 month No ventricular tachyarrhythmias require ongoing treatment No unstable angina Pulmonary No severe asthma require chronic systemic steroid Other HIV negative Negative pregnancy test Fertile patient must use effective contraception No malignancy within past 2 year except basal cell squamous cell skin cancer , superficial bladder cancer , localize prostate cancer Patients undergone potentially curative therapy deem low risk recurrence eligible No medically significant psychiatric disease ( e.g. , endogenous depression , psychosis , bipolar disease ) require hospitalization No prior active autoimmune disease Medically control diabetes thyroid dysfunction allow No clinically significant acute viral bacterial infection require specific therapy PRIOR CONCURRENT THERAPY : Biologic therapy No prior interleukin2 No prior interferon alfa No concurrent cytokine biological response modifier except epoetin alfa case hematologic compromise No concurrent tumor vaccines No concurrent monoclonal antibody No concurrent bone marrow/stem cell transplantation Chemotherapy No concurrent cytotoxic agent Endocrine therapy No concurrent highdose systemic steroid Concurrent lowdose corticosteroid ( e.g. , asthma inhaler , topical cream , intraarticular injection ) allow No concurrent hormonal therapy ( include megestrol ) Concurrent hormone replacement therapy oral contraceptive allow Radiotherapy At least 4 week since prior radiotherapy No concurrent radiotherapy Surgery See Disease Characteristics At least 4 week since prior major surgery Concurrent nephrectomy allow Other At least 14 day since prior antiinfectious therapy No concurrent investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>stage IV renal cell cancer</keyword>
</DOC>